Abstract: ［Abstract］The incidence of patients with diabetic dyslipidemia is very high ,so it is beneficial for their long-term prognosis to control dyslipidemia in patients with diabetes mellitus. With regard to diabetes combined with dyslipidemia, low-density lipoprotein cholesterol is still the primary target of lipid-lowering therapy. But apolipoprotein B is another new important target for lipid-lowering treatments in the latest guidelines, and a lower low-density lipoprotein cholesterol concentration is set for diabetic patients with the very high-risk cardiovascular risk. Statin is still the cornerstone in lipid-lowering therapy. Not only ezetimibe but, lately, proprotein convertase subtilisin/kexin type 9 inhibitors could be used as combination drugs, if the targets cannot achieve with statins alone.

Key words: diabetes mellitus, dyslipidemias, lipoproteins, LDL